During the past decade, Centrum für Hämatologie und Onkologie Bethanien conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 4 clinical trials were completed, i.e. on average, 23.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centrum für Hämatologie und Onkologie Bethanien" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Fondazione Michelangelo" with 2 trials sponsored, "German Breast Group" with 2 trials sponsored, "German CLL Study Group" with 2 trials sponsored and "University Hospital Tuebingen" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centrum für Hämatologie und Onkologie Bethanien" #1 collaborator was "Austrian Breast & Colorectal Cancer Study Group" with 3 trials as a collaborator, "Cancer Trials Ireland" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "German Breast Group" with 2 trials as a collaborator and "NSABP Foundation Inc" with 2 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Centrum für Hämatologie und Onkologie Bethanien" are "Breast Cancer" (7 trials), "Metastatic Breast Cancer" (4 trials), "Multiple Myeloma" (3 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Lymphoid Leukemia" (1 trials). Many other conditions were trialed in "Centrum für Hämatologie und Onkologie Bethanien" in a lesser frequency.

Most popular intervention types in "Centrum für Hämatologie und Onkologie Bethanien" are "Drug" (21 trials), "Biological" (4 trials), "Other" (2 trials), "Procedure" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Cyclophosphamide" (3 trials), "Lenalidomide" (3 trials), "Obinutuzumab" (3 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centrum für Hämatologie und Onkologie Bethanien" are 18 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Centrum für Hämatologie und Onkologie Bethanien". undefined are not yet recruiting, 4 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Centrum für Hämatologie und Onkologie Bethanien, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum für Hämatologie und Onkologie Bethanien, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Centrum für Hämatologie und Onkologie Bethanien has several departments that took part in Clinical trials: "Centrum für Hämatologie und Onkologie Bethanien" - 2 trials